Travere Therapeutics, Inc.
FILSPARI
Focal Segmental Glomerulosclerosis (FSGS)
Resolved
175days ago
Approval decision · Jan 13, 2026
What's at stake
A final FDA approval decision on FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) is expected Jan 13, 2026.
Primary source
· SEC 8-K
verified 17h ago
“The Company’s PDUFA target action date for its sNDA seeking full approval for FILSPARI in FSGS is January 13, 2026.”